These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8618963)

  • 41. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ion selectivity of porcine skeletal muscle Ca2+ release channels is unaffected by the Arg615 to Cys615 mutation.
    Shomer NH; Mickelson JR; Louis CF
    Biophys J; 1994 Aug; 67(2):641-6. PubMed ID: 7948678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular pathology of malignant hyperthermia and central core disease].
    Takagi A
    Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
    Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Are morphologic changes in skeletal muscles of patients with malignant hyperthermia diagnostically useful?].
    Anetseder M; Pohl F; Klein R; Müller R; Hoyer A; Horbaschek H; Roggendorf W; Hartung E; Roewer N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Oct; 34(10):626-33. PubMed ID: 10548959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced Mg2+ inhibition of Ca2+ release in muscle fibers of pigs susceptible to malignant hyperthermia.
    Owen VJ; Taske NL; Lamb GD
    Am J Physiol; 1997 Jan; 272(1 Pt 1):C203-11. PubMed ID: 9038826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
    Censier K; Urwyler A; Zorzato F; Treves S
    J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of CACNA1S in predisposition to malignant hyperthermia.
    Carpenter D; Ringrose C; Leo V; Morris A; Robinson RL; Halsall PJ; Hopkins PM; Shaw MA
    BMC Med Genet; 2009 Oct; 10():104. PubMed ID: 19825159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia.
    Treves S; Larini F; Menegazzi P; Steinberg TH; Koval M; Vilsen B; Andersen JP; Zorzato F
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):661-5. PubMed ID: 8053891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of proton release from cultured human myotubes to identify malignant hyperthermia susceptibility.
    Klingler W; Baur C; Georgieff M; Lehmann-Horn F; Melzer W
    Anesthesiology; 2002 Nov; 97(5):1059-66. PubMed ID: 12411787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinct immunopeptide maps of the sarcoplasmic reticulum Ca2+ release channel in malignant hyperthermia.
    Knudson CM; Mickelson JR; Louis CF; Campbell KP
    J Biol Chem; 1990 Feb; 265(5):2421-4. PubMed ID: 2154446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of theophylline on anesthetized malignant hyperthermia-susceptible pigs.
    Fiege M; Weisshorn R; Kolodzie K; Wappler F; Gerbershagen MU
    J Biomed Biotechnol; 2011; 2011():937479. PubMed ID: 22131820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Malignant hyperthermia.
    Kim DC
    Korean J Anesthesiol; 2012 Nov; 63(5):391-401. PubMed ID: 23198031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Malignant hyperthermia: molecular defects in membrane permeability.
    Cheah KS; Cheah AM
    Experientia; 1985 May; 41(5):656-61. PubMed ID: 3888661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calcium accumulation by sarcoplasmic reticulum in whole muscle homogenate preparations of malignant hyperthermia diagnostic patients and pigs.
    Cheah KS; Cheah AM; Fletcher JE; Rosenberg H
    Acta Anaesthesiol Scand; 1990 Feb; 34(2):114-9. PubMed ID: 2305611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetics and pathogenesis of malignant hyperthermia.
    Jurkat-Rott K; McCarthy T; Lehmann-Horn F
    Muscle Nerve; 2000 Jan; 23(1):4-17. PubMed ID: 10590402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia.
    López JR; Alamo L; Caputo C; Wikinski J; Ledezma D
    Muscle Nerve; 1985 Jun; 8(5):355-8. PubMed ID: 16758579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal relaxation rates in subjects susceptible to malignant hyperthermia.
    Lennmarken C; Rutberg H; Henriksson KG
    Acta Neurol Scand; 1987 Feb; 75(2):81-3. PubMed ID: 3577679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anomalous K
    Vellecco V; Martelli A; Bibli IS; Vallifuoco M; Manzo OL; Panza E; Citi V; Calderone V; de Dominicis G; Cozzolino C; Basso EM; Mariniello M; Fleming I; Mancini A; Bucci M; Cirino G
    Br J Pharmacol; 2020 Feb; 177(4):810-823. PubMed ID: 31051045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.